# ADRM1

Source: https://onco.cc/targets/adrm1/  
OnCo record `adrm1` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ADRM1 (Proteasomal ubiquitin receptor ADRM1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.

## Summary

Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. This complex plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair.

Open Targets scores its association with cancer at 0.65 (direct and indirect evidence; datatypes clinical 0.99, literature 0.93, genetic association 0.00, somatic mutation 0.23, animal model 0.26).

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: ADRM1 26S proteasome ubiquitin receptor; Proteasomal ubiquitin receptor ADRM1; GP110; Rpn13; ARM1; PSMD16
- Tags: cancer-genes-wave
- Symbol: ADRM1
- Class: other
- Biology: Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. This complex plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair. Within the complex, functions as a proteasomal ubiquitin receptor. Engages and activates 19S-associated deubiquitinases UCHL5 and PSMD14 during protein degradation. UCHL5 reversibly associate with the 19S regulatory particle whereas PSMD14 is an intrinsic subunit of the proteasome lid subcomplex. Location: Cytoplasm; Nucleus (UniProt). Locus 20q13.33 (HGNC).
- Where found: Multiple myeloma: Open Targets association 0.61 with plasma cell myeloma (MONDO_0009693); Non-Hodgkin lymphoma: Open Targets association 0.57 with non-Hodgkin lymphoma (MONDO_0018908); Mantle cell lymphoma: Open Targets association 0.54 with mantle cell lymphoma (MONDO_0018876)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.99. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:15759: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:15759
- UniProt Q16186: https://www.uniprot.org/uniprotkb/Q16186/entry
- NCBI Gene 11047: https://www.ncbi.nlm.nih.gov/gene/11047
- Ensembl ENSG00000130706: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000130706

## Connected records

- collections: [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)

---
JSON: https://onco.cc/api/v1/entities/adrm1.json